Studies of the alpha 2-adrenoceptor affinity and the alpha 2- to alpha 1-adrenoceptor selectivity of some substituted benzoquinolizines using receptor-binding techniques.
D012369:2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy- / Q000378:metabolism*; D000317:Adrenergic alpha-Antagonists / Q000378:metabolism*; D000818:Animals; D001792:Blood Platelets / Q000378:metabolism; D002540:Cerebral Cortex / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D011224:Prazosin / Q000378:metabolism; D011807:Quinolizines / Q000378:metabolism*; D011869:Radioligand Assay; D051381:Rats; D011919:Rats, Inbred Strains; D011942:Receptors, Adrenergic, alpha / Q000378:metabolism*; D014316:Tritium; D015016:Yohimbine / Q000378:metabolism
D000317:Adrenergic alpha-Antagonists; D011807:Quinolizines; D011942:Receptors, Adrenergic, alpha; D014316:Tritium; D015016:Yohimbine; D012369:2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-; D011224:Prazosin